U.S. FDA approves Celgene's Abraxane for pancreatic cancer

Sept 6 Fri Sep 6, 2013 12:34pm EDT

Sept 6 (Reuters) - Celgene Corp's drug Abraxane was approved as a treatment for pancreatic cancer by the U.S. Food and Drug Administration on Friday.

Abraxane is currently approved to treat breast cancer and non-small cell lung cancer. In a clinical trial, patients with pancreatic cancer who received Abraxane plus the chemotherapy gemcitabine lived, on average, 1.8 months longer than those who received gemcitabine alone.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.